Lyell Immunopharma Stock Rises on Positive Clinical Trial Results

Lyell Immunopharma shares are trading higher after the company announced positive new clinical data demonstrating high rates of durable complete responses in their Phase 1/2 trial for LYL314, a treatment for aggressive large B-cell lymphoma.